News about "EBITDA"

Stada Eyes Autumn IPO as Sale Talks Stall and Market Conditions Improve

Stada and its owners are also considering alternative ownership options, including a potential sale. The company previously held talks with private equity firm CapVest, which would have valued Stada at around 10 billion euro including debt. Those discussions have since stalled, prompting a stronger push toward the IPO route.

EBITDA | 29/08/2025 | By Darshana

Sai Life Sciences Eyes Global Expansion as Revenue Hits INR 1,115.1 Crore

The company reported a 15 percent increase in revenue and a 36 percent rise in net profit compared to the same period last year, driven by strong execution, expanding capacity, and deepening customer relationships.

EBITDA | 10/02/2025 | By Aishwarya |  574

Zydus Reports Robust Growth in Q3 FY25 with a 17 Percent Increase in Revenue

Zydus Lifesciences recorded revenue from operations at INR 52,691 million, marking a 17 percent increase year-over-year.

EBITDA | 06/02/2025 | By Aishwarya |  506

OneSource Achieves INR 3,926 Million Revenue in Q3FY25

OneSource demonstrated exceptional profitability with EBITDA reaching INR 1,432 million, an 85 percent increase compared to the previous quarter, resulting in a robust EBITDA margin of 36.5 percent, up by 1,334 basis points quarter-on-quarter.

EBITDA | 01/02/2025 | By Aishwarya |  537

Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25

The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.

EBITDA | 31/01/2025 | By Aishwarya |  830

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

EBITDA | 29/10/2024 | By Aishwarya |  548

Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance

Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.

EBITDA | 23/05/2024 | By Aishwarya |  630

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 19.01 crore in Q1FY24, growth of 26.66% Y-o-Y

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 19.01 crore in Q1FY24, growth of 26.66% Y-o-Y

EBITDA | 11/08/2023 | By Sudeep Soparkar |  643

JB Pharma Records Revenue Growth of 14 Percent to INR 896 Crores in Q1 FY24

For the first quarter of FY24 ended June 30, 2023, JB Pharma recorded revenue of INR 896 crores growing 14 percent from INR 785 crores in the corresponding quarter.

EBITDA | 09/08/2023 | By Manvi |  1000

Milestone Financial Year 2022 - 23 For Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has achieved the milestone of Rs. 533 crore Revenue & Rs. 100 crore Profit before tax for the first time in a financial year. Company has reported its Best-ever results in a financial year with the highest - Revenue, EBITDA and Net Profit during FY 2023.

EBITDA | 30/05/2023 | By Sudeep Soparkar |  557